Autres langues Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Marché Fermé - Nasdaq Autres places de cotation 22:30:01 03/05/2024			Varia. 5j.	Varia. 1 janv.
23,6 ^USD	+1,42 %		+13,68 %	-22,60 %

15/04	Intellia Therapeutics, Inc. nomme Michael P. Dube au poste de directeur comptable	CI
25/03	Intellia Therapeutics met fin à l'accord de développement avec Regeneron Pharmaceuticals	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates	02/05
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024	29/04
Intellia Therapeutics : Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine - Form 8-K	15/04
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	15/04
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	25/03
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	22/03
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	22/03
Intellia Therapeutics : Termination of Material Agreement - Form 8-K	22/03
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18/03
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	18/03
North American Morning Briefing : Traders Await -2-	26/02
Intellia Therapeutics Q4 Loss Widens	22/02
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress	22/02
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis	15/02
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15/02
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	15/02
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	15/02
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Intellia Therapeutics, Inc.

Actions

NTLA

US45826J1051

Autres langues

Filtres